barzolvolimab vs SAR449028

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Spontaneous Urticaria

Shared mechanism: KIT · full Chronic Spontaneous Urticaria pipeline

barzolvolimab

Developed by Celldex Therapeutics

Phase 3 in Chronic Spontaneous Urticariamonoclonal antibody
Partial signal

NCT06455202 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled Phase 3 in chronic spontaneous urticaria. Its primary endpoint, UAS7 change at week 12, is a validated clinical scale and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate.

Next expected readout: September 2028 · NCT07256392 (registry estimate)

Reported efficacy

Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score) (From Day 1 (first dose) to Day 85 (Week 12)): Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). (met)

Result source: NCT06445023

SAR449028

Developed by Sanofi

undisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Spontaneous Urticaria

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

SAR449028: no structured comparison results are available for Chronic Spontaneous Urticaria.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

barzolvolimab
Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06455202 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06445023 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: barzolvolimab's landscape · SAR449028's landscape